Novo Nordisk A/S (NVO)
122.75
-1.78
(-1.43%)
USD |
NYSE |
Apr 18, 16:00
122.50
-0.25
(-0.20%)
After-Hours: 20:00
Novo Nordisk Cash from Financing (TTM): -9.170B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.170B |
| September 30, 2023 | -9.114B |
| June 30, 2023 | -7.964B |
| March 31, 2023 | -7.430B |
| December 31, 2022 | -7.343B |
| September 30, 2022 | -5.268B |
| June 30, 2022 | -5.322B |
| March 31, 2022 | -4.597B |
| December 31, 2021 | -4.056B |
| September 30, 2021 | -4.695B |
| June 30, 2021 | -4.779B |
| March 31, 2021 | -5.293B |
| December 31, 2020 | -4.940B |
| September 30, 2020 | -5.818B |
| June 30, 2020 | -5.400B |
| March 31, 2020 | -5.257B |
| December 31, 2019 | -5.321B |
| September 30, 2019 | -5.244B |
| June 30, 2019 | -5.384B |
| March 31, 2019 | -5.195B |
| December 31, 2018 | -5.468B |
| September 30, 2018 | -5.255B |
| June 30, 2018 | -5.690B |
| March 31, 2018 | -5.798B |
| December 31, 2017 | -5.432B |
| Date | Value |
|---|---|
| September 30, 2017 | -5.476B |
| June 30, 2017 | -5.075B |
| March 31, 2017 | -5.207B |
| December 31, 2016 | -5.780B |
| September 30, 2016 | -5.875B |
| June 30, 2016 | -5.000B |
| March 31, 2016 | -4.842B |
| December 31, 2015 | -4.478B |
| September 30, 2015 | -4.523B |
| June 30, 2015 | -4.354B |
| March 31, 2015 | -4.489B |
| December 31, 2014 | -4.732B |
| September 30, 2014 | -4.574B |
| June 30, 2014 | -4.531B |
| March 31, 2014 | -4.706B |
| December 31, 2013 | -4.209B |
| September 30, 2013 | -4.048B |
| June 30, 2013 | -3.753B |
| March 31, 2013 | -3.770B |
| December 31, 2012 | -3.478B |
| September 30, 2012 | -3.607B |
| June 30, 2012 | -4.248B |
| March 31, 2012 | -3.486B |
| December 31, 2011 | -3.139B |
| September 30, 2011 | -2.947B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-9.170B
Minimum
Dec 2023
-4.056B
Maximum
Dec 2021
-5.915B
Average
-5.321B
Median
Dec 2019
Cash from Financing (TTM) Benchmarks
| Amgen Inc | 21.05B |
| AstraZeneca PLC | -6.567B |
| Sanofi SA | -- |
| Viking Therapeutics Inc | 271.38M |
| Evaxion Biotech AS | -- |